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Abstract
Metaplastic breast carcinoma (MBC) is a rare subtype of breast cancer characterized by coexistence of carcinomatous
and sarcomatous components. Snail is a nuclear transcription factor incriminated in the transition of epithelial to
mesenchymal differentiation of breast cancer. Aberrant Snail expression results in lost expression of the cell adhesion
molecule E-cadherin, an event associated with changes in epithelial architecture and invasive growth. We aimed to
identify the utility of Snail, and of traditional immunohistochemical markers, in accurate MBC classification and to
evaluate clinicopathologic characteristics and outcome.
We retrospectively reviewed 34 MBC cases from January 1997 to September 2007. The control group contained
26 spindle cell lesions. Immunohistochemistry used Snail, p63, epidermal growth factor receptor (EGFR), OSCAR,
and wide spectrum cytokeratin (WS-KER). Negative was a score less than 1%. We found that Snail and EGFR are
sensitive (100%) markers with low specificity (3.8% and 19.2%) for detecting MBC. p63 and WS-KER are specific
(100%), with moderate sensitivity (67.6% and 76.5%); OSCAR is sensitive (85.3%) and specific (92.3%). A combination
of any 2 of the p63, OSCAR, and WS-KER markers increased sensitivity and specificity. MBCs tended to be high-
grade (77%), triple negative (negative for estrogen receptor, progesterone receptor, and HER2) [27/33; 81.8%], and
carcinomas with low incidence of axillary lymph node involvement (15%), and decreased disease-free [71% (95%CI:
54%, 94%) at 3 yrs.) and overall survival. A combination of p63, OSCAR and WS-KER are useful in its work-up. On
the other hand, Snail is neither a diagnostic nor a prognostic marker for MBC.
Background
Metaplastic breast carcinoma (MBC) is a rare subtype of
breast cancer characterized by carcinomatous and sarco-
matous components. Clinically, MBCs have a large size
at diagnosis, lack expression of hormone receptors, and
have a lower incidence of regional lymph nodes and a
higher rate of systemic disease than ductal carcinomas
of the breast [1]. Thus, the likelihood for recurrence of
MBC is high, translating into a poor outcome. MBCs
comprise less than 5% of mammary adenocarcinomas,
and they generally present as rapidly growing, palpable
tumors with circumscribed contours and a high-density
mass with associated architectural distortion radiogra-
phically [1-3].
Customarily, MBCs are divided into 2 main categories:
squamous and heterologous or pseudosarcomatous
metaplasia. They have lower frequency of axillary lymph
node metastases than non-metaplastic high-grade carci-
nomas [1]. Prognosis of MBC is determined by stage at
diagnosis. It is unclear whether the histologic type of
metaplasia has a significant effect on prognosis.
Transformation of the carcinomatous component into
the sarcomatous component through epithelial-to-
mesenchymal transition could explain the origin of the
MBC [4]. This transition is a physiologic program used
in embryogenesis and also activated during cancer inva-
sion, progression and metastasis, in which cancer cells
lose their adherent and polarity features and change
into a mesenchymal phenotype with a more elongated
cellular shape for increasing motility.
Association of breast cancer and epithelial-to-
mesenchymal transition has been described in the medi-
cal literature [5], and now its role in the generation of
the breast cancer stem cell phenotype has acquired a
heightened interest [6,7]. Indeed, the tumoral microen-
vironment enhances extracellular stimuli such as
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itate migration and invasion.
Epithelial-to-mesenchymal transition has been related
to upregulation of the transcriptional repressor Snail [8],
which is associated with loss of the epithelial adhesion
molecule E-cadherin [9,10], and predicts a worse out-
come in progression-free survival for women with breast
cancer [8]. High Snail expression in breast cancers found
with microarray analysis was significantly associated with
a poor relapse-free survival in nonmetaplastic breast
carcinomas [11-13]. Moreover, Snail expression predicts
disease-free survival independently of lymph node status
and tumor size [8]. A negative correlation was
shown between Snail and estrogen receptor expression
driven by the MTA3 (metastasis-associated protein)
pathway [14].
Accurate diagnosis and differentiation of MBC from
other spindle cell lesions of the breast can be challen-
ging, especially in core needle biopsies [15]. In the pre-
sent study, our primary aim was to study and compare
Snail with other known traditional immunomarkers
used in identifying MBC and to evaluate its correlation
with tumor characteristics and outcome. Our secondary
aim was to review our experience in the multidisciplin-
ary management of MBC cases over a 10-year period,
examining clinicopathologic features, treatment, and
outcomes.
Materials and methods
Tissue specimens
The study was approved by the institutional review boards
of our respective Institution. We conducted a retrospective
review of 34 patients who received a diagnosis of MBC at
a tertiary referral center from February 1997 to August
2007. Patient age, tumor size and grade, nodal status, hor-
mone receptor status, initial treatment, recurrence, and
follow up information were reviewed (Table 1).
The cases of MBC contained 20 cases of spindle cell
type, 5 mixed spindle and squamous cell type, 4 squamous
cell type, 3 matrix producing type, and 2 low-grade ade-
nosquamous carcinoma. All patients with MBC were
females with an average age of 62 yrs. (range: 32 - 90 yrs.).
All tumors were characterized histologically according to
Wartgotz’s criteria [16-19]. The control group consisted of
26 spindle cell lesions: 14 phyllodes tumors, 8 pseudoan-
giomatous stromal hyperplasias (PASH), and 4 myofibro-
blastomas. The majority of the patients in the control
group were females (23) with only few males (3) who pre-
sented with myofibroblastoma. The average age in the
control group is 53 yrs. (range: 17 - 86 yrs.).
Immunohistochemistry
The following immunohistochemical stains were per-
formed: Snail, epidermal growth factor receptor (EGFR),
OSCAR (a broad spectrum cytokeratin), wide spectrum
cytokeratin (WS-KER) and p63, using these antibodies
and positive controls listed in Table 2. Negative controls
were run simultaneously and had primary antibody
replaced with buffer. EGFR immunostain was performed
Table 1 Clinicopathologic factors of 34 patients with
metaplastic breast carcinoma
Age (years), mean (range) 61.8 (32-90)
Histologic grade, n (%)
Low grade 6 (17.6%)
Intermediate grade 2 (5.9%)
High grade 26 (76.5%)
Histologic subtypes
Spindle cell 20 (58.8%)
Mixed squamous and spindle cell 5 (14.7%)
Squamous 4 (11.8%)
Matrix producing 3 (8.8%)
Adenosquamous 2 (5.9%)
Tumor diameter (cm), median
(range)
3.0 (0.8-24)
Tumor size T1 10
(29.4%)
T2 14
(41.2%)
T3 6 (17.6%)
T4 4 (11.8%)
Receptor Status
ER positive 4 (12.1%)
PR positive 3 (9.1%)
Her2 positive 2 (5.9%)
Lymph node status
Positive 5 (14.7%)
Negative 29 (85.3%)
Surgery
Mastectomy 21 (61.8%)
BCT 13 (38.2%)
Adjuvant treatment
Chemotherapy 14 (41.2%)
Radiation 17 (50.0%)
Recurrence Local 3 (8.8%)
Distant 4 (11.8%)
Overall survival, median (95% CI*)
1 year 82.8% (70.1%,
97.8%)
3 years 58.4% (42.0%,
81.4%)
Disease-free survival, median (95%
CI*)
1 year 78.5% (64.4%,
95.5%)
3 years 71.3% (54.4%,
93.6%)
*CI = Confidence Interval
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Page 2 of 10with kits approved by the Food and Drug Administra-
tion (EGFR PharmDX;, Dako North America, Inc,
Carpinteria, California) used in accordance with manu-
facturer instructions for antigen retrieval and immunos-
taining method. Antigen retrieval for all other
antibodies was conducted in citrate buffer (pH, 6.0)
under a pressure of 15 pounds per square inch for
3 minutes. The EnVision+ Dual Link Kit (Dako) was
used for all immunostaining, with an automated slide
stainer and with diaminobenzidine as chromogen and
hematoxylin as counterstain.
Immunohistochemical staining was performed as fol-
lows. Formalin-fixed, paraffin-embedded samples, cut at
5 μm onto charged slides and baked at 60°C for 40 min-
utes prior before staining, were deparaffinized with
3 changes of xylene and rehydrated in a series of graded
alcohols (100% ethanol, 95% ethanol, and 70% ethanol),
then rinsed well in running distilled water. Slides were
placed in a preheated citrate retrieval buffer (pH, 6.0)
for 30 minutes, in a water steamer, cooled in the buffer
for 5 minutes, and rinsed for 5 minutes in running dis-
tilled water.
Slides were placed on an automated slide stainer
(AS100 Autostainer Plus; DAKO, Carpinteria, CA) for
the following procedure (at room temperature). Sections
were incubated with 3% hydrogen peroxide in ethanol
for 5 minutes to inactivate endogenous peroxidases.
They then were incubated in primary antibody for 30
minutes, rinsed with TBST wash buffer (S3006, Tris-
Buffered Saline with Tween 20; DAKO) and incubated
for 15 minutes with a peroxidase-labeled polymer conju-
gated to the secondary antibody. After a rinse with
TBST wash buffer, sections were incubated in
3,3’-diaminobenzidine (K3468, DAB+ Substrate
Chromogen; Dako) for 5 minutes, counterstained with
modified Schmidt’s hematoxylin for 5 minutes, followed
by a 3- minute tap water rinse to set counterstain, dehy-
drated through graded alcohols (70% ethanol, 95% etha-
nol, and 100% ethanol), cleared in 3 changes of xylene,
and mounted with permanent mounting media.
Antibody staining was membranous for EGFR, nuclear
for PIN2 cocktail (p63) and Snail, and cytoplasmic for
OSCAR and WS-KER. For all markers, scoring was per-
formed using a score of less than 1% as negative. Several
different microscopic fields (at least 10) per low and med-
ium-power fields are examined for staining assessment.
Statistical Analysis
Results were analyzed statistically with the sensitivity,
specificity, and positive and negative predictive values
for the different antibodies studied. Disease-free survival
and overall survival were analyzed by the Kaplan-Meier
survival curves. Associations of overall survival and sur-
gery type, chemotherapy and radiotherapy were per-
formed using the log rank test. Associations of tumor
characteristics and snail percentage were assessed using
Wilcoxon rank sum tests, while the association between
snail percentage and age or tumor size was assessed
using linear regression. In all cases, significance was
defined as p-value < 0.05.
Results
Clinicopathologic characteristics (Table 2)
A total of 34 patients were identified (mean age, 61.8 y
[range, 32-90 y]). Of them, 29 patients (85%) presented
with a palpable lump and 5 (15%) had an abnormal
mammogram; 27 (81.8%) patients had triple-negative
hormonal receptor status (negative for estrogen recep-
tor, progesterone receptor, and HER2). Approximately
76% (26/34) of patients have high-grade tumors. The
distribution of tumor sizes was 10 patients with T1, and
14, 6 and 4 patients with T2, T3 and T4 tumors
respectively.
All patients had sentinel lymph node biopsy (100%),
and only four patients had axillary lymph node (ALN)
dissection (30.8%; 4/13). Five (15%) patients were lymph
node positive. Those with positive ALNs have larger
(pT2 or above) tumor size (p = 0.02). Twenty-one (62%)
patients underwent mastectomy and 13 (38%) under-
went breast conservation therapy (BCT). Fourteen
patients (41%) received chemotherapy and seventeen
(50%) patients received radiotherapy, 13 of whom
received breast radiation as part of BCT. Neither che-
motherapy nor radiotherapy increased survival of these
patients (p = 0.87 and 0.13, respectively). Two patients
were lost to follow up, with a median follow-up time of
21 months for the remaining 32. Three patients had
local recurrences which occurred within 6 months, and
Table 2 Immunohistochemical stains used, including their clones, dilutions, source and controls
Antibody Monoclonal/polyclonal Clone Dilution Source Positive Control
SNAIL M AbcamAb17732 1:500 DAKOCarpinteria, CA Breast cancer
EGFR M DAKO kit prediluted DAKOCarpinteria, CA Colon cancer
OSCAR M OSCAR 1:200 DAKOCarpinteria, CA Tonsil
WS-KER P Cytokeratin Wide Spectrum (WSS) 1:1600 DAKOCarpinteria, CA Breastcancer
P63 M PIN2 cocktail prediluted DAKOCarpinteria, CA Prostate cancer
EGFR = epidermal growth factor receptor; WS-KER = wide spectrum keratin
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Page 3 of 104 had distant metastases to lung and bone. Five patients
died within the first year of diagnosis, 9 additional
patients died by 5 years, and 2 more died by 10 years.
The Kaplan-Meier estimated disease-free survival and
95% confidence interval (CI) was found to be 78.5%
(64.4%, 95.5%) at 1 year and 71.3% (54.4%, 93.6%) at 3
years. The Kaplan-Meier estimated overall survival and
95% CI was found to be 82.8% (70.1%, 97.8%) at 1 year
and 58.4% (42.0%, 81.4%) at 3 years as shown in Figure 1.
Patients treated with BCT had statistically better overall
survival than those with mastectomy (p = 0.029 by log
rank test) as shown in Figure 2. This is partly attributed
to lower tumor size (pT) in patients who underwent BCT
(median tumor size is 1.5 cm) than those who had mas-
tectomy (median tumor side is 4.8 cm) [p < 0.0001].
Although not statistically significant (p = 0.828), mastect-
omy patients more frequently had high grade tumors
(81%) compared with BCT patients (69%). Finally, survi-
val of these patients was not associated with age, tumor
size, grade, ALN status, hormone receptor and HER2 sta-
tus, and type of treatment (all p > 0.06).
Immunohistochemical analysis
The results of the immunohistochemical analyses are as
shown in Tables 3 &4 and Figures 3 &4. Snail was a
sensitive (100%) marker for identifying MBC. However
it was not a specific (3.8%) marker, as it was seen in
other spindle cell lesions, including myofibroblastoma
(4/4; 100%); phyllodes tumor (14/14; 100%) and PASH
(7/8; 87.5%).
EGFR was also a sensitive marker (100%) but had a
low specificity (19.2%), whereas p63 was a very specific
marker (100%) for MBC but had a lower sensitivity
(67.6%) compared to both EGFR and Snail. OSCAR ker-
atin and WS-KER were both comparable in their sensi-
tivity (85.3% and 76.5% respectively) and specificity
(92.3% and 100% respectively) for detecting MBC. When
several of those immunomarkers (OSCAR, p63 and
WS-KER) were combined, both the sensitivity (82.4 to
88.2%) and specificity (92.3 to 100%) were increased,
with the combination of p63 and WS-KER being the
best two antibodies for detecting MBC in terms of high
specificity (100%).
Figure 1 Overall and disease-free survival of patients with MBC.
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survival
Snail expression (percentage of tumor cells staining) did
not correlate with age, tumor size, grade, type of surgery
(mastectomy vs. BCT), ALN status, hormone receptor
and HER2 status, and type of treatment (hormonal ther-
apy vs. chemotherapy vs. radiotherapy) (all p > 0.10).
Furthermore, it did not correlate with survival (Hazard
Ratio = 1.02; 95% CI: 0.98, 1.06; p = 0.45).
Discussion
Our findings confirm findings from other studies report-
ing that the majority of MBC are high grade, hormone
receptor negative and ALN negative. Despite presenting
as node negative disease, the overall survival is low. We
did not observe a significant difference with respect to
overall survival between those who did and did not
receive chemotherapy (p = 0.87 by log rank test),
although the sample size is small. Similarly, no differ-
ence was seen between those who did and did not get
radiotherapy (p = 0.13 by log rank test).
Figure 2 Survival of patients with BCT and mastectomy for treatment of MBC.
Table 3 Immunoexpression of the different markers in MBC, myofibroblastomas phyllodes tumor, and PASH
Antibody MBC (%) Myofibroblastoma (%) Phyllodes Tumor (%) PASH (%)
SNAIL 34/34 (100%) 4/4 (100%) 14/14 (100%) 7/8 (87.5%)
EGFR 34/34 (100%) 0/4 (0%) 13/14 (92.9%) 8/8 (100%)
OSCAR 29/34 (85.3%) 0/4 (0%) 2/14 (14.3%) 0/8 (0%)
WS-KER 26/34 (76.5%) 0/4 (0%) 0/14 (0%) 0/8 (0%)
P63 23/34 (56.7%) 0/4 (0%) 0/14 (0%) 0/8 (0%)
MBC = metaplastic breast carcinoma
PASH = pseudoangiomatous stromal hyperplasia
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expression as related to ductal or lobular cancer sub-
types, tumor grade, or luminal versus basal array profile
[8], but metaplastic carcinomas were not included in the
analyses. In another study, Blanco et al. [20] did not
find differences in Snail expression related to histologic
type, lymph node disease and high-moderate tumor
grade [20]. Similarly, we did not find any significant
association between Snail expression and other clinico-
pathologic factors (age, tumor size, grade, type of sur-
gery, ALN status, hormone receptor and HER2 status,
and type of treatment).
Breast conservation appears to be a reasonable treat-
ment option with better survival than mastectomy.
Although most MBC are high grade, there are a few var-
iants that are low grade and behave indolently, such as
low grade adenosquamous [21] and fibromatosis-like
spindle cell carcinoma [22,23]. Several investigators sug-
gest that those variants of MBC can be treated with
BCT if the tumor size allows [21,22]. Dave et al. [24]
have found that breast conservation to be a reasonable
treatment option with equivalent survival to mastect-
omy, and adjuvant radiation is essential for achieving
high local control rates after conservative surgery [24].
Matrix-producing carcinoma and biphasic metaplastic
sarcomatoid carcinoma (carcinosarcoma) are aggressive
subtypes of MBC with a worse clinical outcome than
conventional invasive ductal carcinoma (IDC) with a
decreased locoregional recurrence-free survival (p =
0.001) and decreased distant recurrence-free survival
(p = 0.001) [25]. Several investigators are suggesting
modified radical mastectomy with adjuvant treatment
(radiation and/or chemotherapy) for patients with
aggressive subtypes of MBC, particularly for patients
with T2 and higher stage disease [25,26]. Dave et al.
[24] have shown BCT is equivalent to mastectomy in
terms of survival. In our study, we found patients
treated with BCT to have significantly better survival
than those treated with mastectomy. Those patients
treated with BCT presented with smaller tumor size
and, generally, better tumor grade, indicating they may
have had less severe disease.
Unlike our study and others [24,27], Khan et al. [28]
and Sayed at al [29], have found higher rates of axillary
lymph node involvement (40% and 53% respectively),
and therefore proposed axillary lymph node staging.
Furthermore, several investigators found that positive
axillary nodes at presentation are strongly associated
with worse survival [24,30]. In our study, only 4 of 13
(30.8%) patients have axillary lymph node involvement
at presentation, although 21 did not have axillary nodes
assessed.
Overall, MBC has a worse disease-free survival, and a
significantly decreased overall survival, when compared
to typical conventional breast carcinoma [1,28,29]. How-
ever, Gibson et al. [31] have found that survival in MBC
appears to be similar to that of conventional ductal ade-
nocarcinoma, when stratified by stage [31]. Furthermore,
they did not find adjuvant chemotherapy to be of bene-
fit, by multivariate analysis [31]. Using multivariate ana-
lysis, they also did not find an impact on recurrence or
survival with regard to tumor size, age, menopausal sta-
tus, nodal status, histologic subtype, adjuvant therapy, or
extent of surgery [31]. In our study, we also found no
difference in survival associated with age, tumor size,
grade, ALN status, hormone receptor and HER2 status,
or type of treatment, likely due to the small sample size
providing limited statistical power.
MBC usually develop hematogenous metastases (lung
and bone), in keeping with the sarcomatous phenotype
[29,32]. Usually, MBC tends to be estrogen and proges-
terone receptor negative [28,29]. Metaplastic carcinomas
are thought to be of basal-cell phenotype based on
immunohistochemical profile [33], and therefore most
Table 4 Sensitivity, Specificity, Positive (PPV) and Negative (NPV) Predictive Values of the different
immunomarkers (%)
Stains vs. Case N Overall
Agreement, %
(95% CI)
Sensitivity, % (95% CI) Specificity, % (95% CI) PPV NPV
EGFR 60 65.0 (52.4, 75.8) 100.0 (89.9, 100.0) 19.2 (8.5, 37.9) 61.8 100.0
OSCAR 60 88.3 (77.8, 94.2) 85.3 (69.9, 93.6) 92.3 (75.9, 97.9) 93.6 82.8
P63 60 81.7 (70.1, 89.4) 67.6 (50.8, 80.9) 100.0 (87.1, 100.0) 100.0 70.3
SNAIL 60 58.3 (45.7, 71.8) 100.0 (89.9, 100.0) 3.8 (0.7, 18.9) 57.6 100.0
WSKER 60 86.7 (75.8, 93.1) 76.5 (60.0, 87.6) 100.0 (87.1, 100.0) 100.0 76.5
OSCAR & P63 & WSKER 60 90.0 (79.9, 95.3) 88.2 (73.4, 95.3) 92.3 (75.9. 97.9) 93.8 85.7
OSCAR & WSKER 60 88.3 (77.8, 94.2) 85.3 (69.9, 93.5) 92.3 (75.9, 97.9) 93.6 82.8
OSCAR & P63 60 90.0 (79.9, 95.3) 88.2 (73.4, 95.3) 92.3 (75.9. 97.9) 93.8 85.7
P63 & WSKER 60 90.0 (79.9, 95.3) 82.4 (66.5, 91.7) 100.0 (87.1, 100.0) 100.0 81.2
EGFR = epidermal growth factor receptor; WS-KER = wide spectrum keratin
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Page 6 of 10Figure 3 High grade squamous cell carcinoma (A; H&E - 40×) with positive staining for OSCAR (B; 40×), p63 (C; 40×), WS-KER (D; 40×),
SNAIL (E; 60×) and EGFR (F; 60×).
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Page 7 of 10Figure 4 High grade spindle carcinoma (A; H&E - 40×) with positive staining for OSCAR (B; 40×), p63 (C; 40×), WS-KER (D; 40×), SNAIL
(E; 60×) and EGFR (F; 60×).
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Page 8 of 10likely will express basal keratins (CK5/6, CK14) [15]. A
subset of MBC (specifically adenosquamous carcinoma)
arises in association with papillomas or complex scleros-
ing lesions [34,35].
Since MBC mimic other spindle cell lesions of the
breast, immunohistochemistry, specifically the use of
cytokeratins, are valuable in differentiating between the
two entities [22,23,27,36]. Carter et al. [27] found that
pankeratin (MNF116) is the most sensitive marker
(93%), followed by cytokeratins 14 (90%) for identifying
MBC. Other markers that are positive in MBC but to a
lesser extent include CAM 5.2 (40%) and AE1/3 (41%)
[27]. Several recent studies have described that some
metaplastic carcinomas exhibit myoepithelial differentia-
tion. Dunne et al. [15] reported at least focal staining
for smooth muscle actin (SMA) in 79% (11/14) of MBC.
In addition, they noted frequent expression of the basal
cell and myoepithelial keratins 34 bE12, CK5 and CK14
[15]. Reis-Filho et al. [37] also found frequent positivity
for SMA and CK14, as well as immunoreactivity for
S100 protein, p63, and the novel myoepithelial markers,
maspin and p-cadherin. Other investigators have identi-
fied consistent expression of maspin and cadherins in
sarcomatoid breast carcinoma [38]. Koker and Kleer
[39] reported expression of p63 in all 10 spindle cell
carcinomas examined, compared with 1 of 174 (0.6%) of
nonmetaplastic breast carcinomas and 0 of 10 phyllodes
tumors. In a study of 20 spindle cell metaplastic carci-
nomas, Leible et al. [40] found positive staining for p63
(70%), SMA (60%), S100 protein (45%) and CD10 (80%),
in addition to frequent immunoreactivity for maspin,
CD29, and 14-3s (markers that appear to be preferen-
tially expressed in myoepithelial cells). Tse et al. [41]
found p63 to be a useful marker in the diagnosis of
MBC with a sensitivity of 65%, specificity of 96%, a PPV
and NPV of 96% and 66%, respectively, and an accuracy
of 78%. In our study, we have found that OSCAR, WS-
KER and p63 to be the most sensitive and specific mar-
kers for identifying MBC.
Although EGFR is expressed in MBC (66%), no EGFR
or KIT activating mutations are present [33]. aB-crystal-
lin is another novel marker found to be highly expressed
in MBC (86%) [42]. The present study is the first to
evaluate Snail as a possible marker for diagnosis of
MBC. Although Snail is a sensitive marker (100%), it
has a low specificity (3.8%) because it is expressed pro-
miscuously in other spindle cells lesions of the breast.
Conclusions
Snail is neither a good diagnostic nor a prognostic mar-
ker for MBC. MBC tend to be high grade, triple-nega-
tive (negative for estrogen and progesterone receptors
and HER2) carcinomas with few axillary lymph node
metastases and reduced overall survival. Our findings
support the diagnostic utility of p63, OSCAR and
WS-KER as a panel in the diagnosis of MBC and in the
differentiation of these tumors from other spindle cell
lesions of the breast.
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